---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016231"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T04:51:16.463567+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CFIUS extends review of Mustang Bio facility sale to uBriGene into second 45-day phase

## Summary
- CFIUS initial 45-day review completed Sep 28, 2023 but not concluded; transitions to second 45-day investigation.
- CFIUS investigation to be completed no later than November 13, 2023.
- Deal involves sale of Mustang's Worcester cell processing facility and manufacturing assets to uBriGene, a Chinese CDMO subsidiary.
- CFIUS clearance was voluntarily submitted and not a condition to closing the transaction.

## SEC filing metadata
- accession: 0001558370-23-016231
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837023016231/0001558370-23-016231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837023016231/tmb-20230928x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016231
- JSON: https://secwatch.observer/filing/0001558370-23-016231.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016231.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.